米力农联合rhBNP治疗慢性心力衰竭的疗效及其对患者心、肺功能的影响

The Efficacy of Milrinone Combined with rhBNP in the Treatment of Chronic Heart Failure and its Impact on Heart and Lung Function of Patients

【目的】探讨米力农联合重组人脑利钠肽(rhBNP)治疗慢性心力衰竭的疗效及其对患者心、肺功能的影响。【方法】回顾性分析2021年10月至2022年10月本院收治的120例慢性心力衰竭患者的临床资料,根据治疗方法不同将其分为观察组(米力农联合rhBNP治疗)与对照组(米力农治疗),每组60例。比较两组治疗效果、不良反应,比较两组治疗前后心功能指标[心排血量(CO)、每搏输出量(SV)、左心室射血分数(LVEF)]、肺功能指标[第1秒用力呼气容积占预计值百分比(FEV_(1)%)、用力肺活量占预计值百分比(FVC%)、FEV_(1)/FVC]及血清BNP、尿酸(UA)水平。【结果】观察组总有效率显著高于对照组(P<0.05)。治疗后,两组CO、SV、LVEF高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。治疗后,两组FEV_(1)%、FVC%、FEV_(1)/FVC高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。治疗后,两组血清BNP、UA水平低于治疗前,且观察组低于对照组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。【结论】米力农联合rhBNP治疗慢性心力衰竭安全有效,可改善患者的心、肺功能,值得临床借鉴。

【Objective】To explore the therapeutic effect of milrinone combined with recombinant human brain natriuretic peptide(rhBNP)in the treatment of chronic heart failure and its impact on the heart and lung function of patients.【Methods】A retrospective analysis was conducted on the clinical data of 120 patients with chronic heart failure admitted to our hospital from October 2021 to October 2022.According to the quality method,they were divided into the observation group(treated with milrinone combined with rhBNP)and the control group(treated with milrinone),with 60 cases in each group.We compared the treatment effects and adverse reactions between two groups,and also compared the heart function indicators[cardiac output(CO),stroke output(SV),left ventricular ejection fraction(LVEF)],lung function indicators[percentage of forced expiratory volume at 1 second to expected value(FEV_(1)%),forced lung activity percentage to expected value(FVC%),FEV_(1)/FVC],as well as serum BNP and uric acid(UA)levels before and after treatment.【Results】The total effective rate of the observation group was significantly higher than that of the control group(P<0.05).After treatment,the CO,SV,and LVEF of the two groups were higher than before treatment,and the observation group was higher than the control group,with statistical significance(P<0.05).After treatment,the FEV_(1)%,FVC%,and FEV_(1)/FVC of the two groups were higher than before treatment,and the observation group was higher than the control group,with statistical significance(P<0.05).After treatment,the serum BNP and UA levels in both groups were lower than before treatment,and the observation group was lower than the control group(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).【Conclusion】The combination of milrinone and rhBNP is safe and effective in treating chronic heart failure,and can improve the heart and lung function of patients,which is worth clinical reference.